Publications
198 results found
Krell J, Stebbing J, 2014, Broader Implications of a Stage-Guided Stratified Therapeutic Approach for AIDS-Related Kaposi's Sarcoma, JOURNAL OF CLINICAL ONCOLOGY, Vol: 32, Pages: 373-375, ISSN: 0732-183X
- Author Web Link
- Cite
- Citations: 10
Frampton AE, Castellano L, Colombo T, et al., 2014, MicroRNAs Cooperatively Inhibit a Network of Tumor Suppressor Genes to Promote Pancreatic Tumor Growth and Progression, GASTROENTEROLOGY, Vol: 146, Pages: 268-+, ISSN: 0016-5085
- Author Web Link
- Cite
- Citations: 132
Stebbing J, Harding V, Urch CE, et al., 2014, The prognostic role of circulating tumor cells in heavily pretreated individuals with a low life expectancy, FUTURE ONCOLOGY, Vol: 10, Pages: 2555-2560, ISSN: 1479-6694
- Author Web Link
- Cite
- Citations: 1
Bidard F-C, Peeters D, Fehm T, et al., 2013, Pooled analysis of circulating tumor cells in metastatic breast cancer: Findings from 1944 individual patients data, CANCER RESEARCH, Vol: 73, ISSN: 0008-5472
Krell D, Mulholland P, Frampton AE, et al., 2013, IDH mutations in tumorigenesis and their potential role as novel therapeutic targets, FUTURE ONCOLOGY, Vol: 9, Pages: 1923-1935, ISSN: 1479-6694
- Author Web Link
- Cite
- Citations: 46
Gall TMH, Frampton AE, Krell J, et al., 2013, Cell-free DNA for the detection of pancreatic, liver and upper gastrointestinal cancers: has progress been made?, FUTURE ONCOLOGY, Vol: 9, Pages: 1861-1869, ISSN: 1479-6694
- Author Web Link
- Cite
- Citations: 5
Gall TMH, Frampton AE, Krell J, et al., 2013, Optimizing Unresectable Colorectal Liver Metastases for Surgery-No Limits, Any Benefits?, JOURNAL OF GASTROINTESTINAL SURGERY, Vol: 17, Pages: 2185-2187, ISSN: 1091-255X
- Author Web Link
- Cite
- Citations: 2
Gall TMH, Frampton AE, Krell J, et al., 2013, Is the detection of circulating tumor cells in locally advanced pancreatic cancer a useful prognostic marker?, EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, Vol: 13, Pages: 793-796, ISSN: 1473-7159
- Author Web Link
- Cite
- Citations: 10
Pinho FG, Frampton AE, Nunes J, et al., 2013, Downregulation of microRNA-515-5p by the Estrogen Receptor Modulates Sphingosine Kinase 1 and Breast Cancer Cell Proliferation, CANCER RESEARCH, Vol: 73, Pages: 5936-5948, ISSN: 0008-5472
- Author Web Link
- Cite
- Citations: 64
de Giorgio A, Krell J, Harding V, et al., 2013, Emerging Roles of Competing Endogenous RNAs in Cancer: Insights from the Regulation of PTEN, MOLECULAR AND CELLULAR BIOLOGY, Vol: 33, Pages: 3976-3982, ISSN: 0270-7306
- Author Web Link
- Cite
- Citations: 62
Lawn AM, Frampton AE, Krell J, et al., 2013, Lymph node ratio can further stratify prognosis in subpopulations of breast cancer patients with axillary nodal metastases, FUTURE ONCOLOGY, Vol: 9, Pages: 1425-1431, ISSN: 1479-6694
- Author Web Link
- Cite
- Citations: 4
Harding V, Afshar M, Krell J, et al., 2013, 'Being there' for women with metastatic breast cancer: a pan-European patient survey, British Journal of Cancer, Vol: 109, Pages: 1543-1548, ISSN: 1532-1827
Background: Understanding their experiences of diagnosis is integral to improving the quality of care for women living withadvanced/metastatic breast cancer.Methods: A survey, initiated in March 2011, was conducted in two stages. First, the views of 47 breast cancer-related patientgroups in eight European countries were sought on standards of breast cancer care and unmet needs of patients. Findings wereused to develop a patient-centric survey to capture personal experiences of advanced breast cancer to determine insights into the‘trade-off’ between extending overall survival and side effects associated with its treatment. The second online survey was open towomen with locally advanced or metastatic breast cancer, or their carers, and responders were recruited through local patientgroups. Data were collected via anonymous local language questionnaires.Results: The online stage II survey received a total of 230 responses from 17 European countries: 94% of respondents had locallyadvanced or metastatic breast cancer and 6% were adult carers. Although the overall experience of care was generally good/excellent (77%), gaps were still perceived in terms of treatment choice and information provision. Treatment choice for patientswas felt to be lacking by 32% of responders. In addition, 68% of those who responded would have liked more information aboutfuture medical treatments and research, with 57% wishing to receive this information from their oncologist. Two-thirds (66%)of women with advanced breast cancer, or their carers, believed life-extending treatment to be important so that they can spendmore time with family and friends, and 67% said that the treatment was worthwhile, despite potential associated side effects.Conclusion: These findings show a continuing need to provide women with advanced breast cancer with better information andemphasise the importance that these patients often place on prolonging survival.
Frampton AE, Krell J, Kazemier G, et al., 2013, Serum miR-1290 as a Marker of Pancreatic Cancer-Letter, CLINICAL CANCER RESEARCH, Vol: 19, Pages: 5250-5251, ISSN: 1078-0432
- Author Web Link
- Cite
- Citations: 3
Krell J, Waxman J, 2013, Reforms in the English National Health Service: the voluntary sector in cancer care provision, LANCET ONCOLOGY, Vol: 14, Pages: 925-926, ISSN: 1470-2045
Krell J, Frampton AE, Colombo T, et al., 2013, The p53 miRNA interactome and its potential role in the cancer clinic, EPIGENOMICS, Vol: 5, Pages: 417-428, ISSN: 1750-1911
- Author Web Link
- Cite
- Citations: 26
Zabron A, Frampton A, Krell J, et al., 2013, SPECIFIC MICRORNA MARKERS ARE IDENTIFIED IN BILE IN PANCREATIC DUCTAL ADENOCARCINOMA, Annual General Meeting of the British-Society-of-Gastroenterology, Publisher: BMJ PUBLISHING GROUP, Pages: A17-A17, ISSN: 0017-5749
- Author Web Link
- Cite
- Citations: 1
Zabron A, Frampton A, Krell J, et al., 2013, BILIARY MICRORNA MARKERS IN BILE AID THE DIAGNOSIS OF CHOLANGIOCARCINOMA AT ERCP, Annual General Meeting of the British-Society-of-Gastroenterology, Publisher: BMJ PUBLISHING GROUP, Pages: A80-A80, ISSN: 0017-5749
Frampton AE, Fletcher CE, Gall TMH, et al., 2013, Circulating peripheral blood mononuclear cells exhibit altered miRNA expression patterns in pancreatic cancer, EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, Vol: 13, Pages: 425-430, ISSN: 1473-7159
- Author Web Link
- Cite
- Citations: 19
Stebbing J, Payne R, Reise J, et al., 2013, The Efficacy of Lapatinib in Metastatic Breast Cancer with HER2 Non-Amplified Primary Tumors and EGFR Positive Circulating Tumor Cells: A Proof-Of-Concept Study, PLOS ONE, Vol: 8, ISSN: 1932-6203
- Author Web Link
- Open Access Link
- Cite
- Citations: 27
Payne SJL, Krell J, Wilson P, et al., 2013, The efficacy of tacrolimus and sirolimus in heavily pre-treated unresectable thymic malignancies, LUNG CANCER, Vol: 80, Pages: 228-229, ISSN: 0169-5002
- Author Web Link
- Cite
- Citations: 2
Frampton AE, Gall TMH, Giovannetti E, et al., 2013, Distinct miRNA profiles are associated with malignant transformation of pancreatic cystic tumors revealing potential biomarkers for clinical use, EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, Vol: 13, Pages: 325-329, ISSN: 1473-7159
- Author Web Link
- Cite
- Citations: 9
Pellegrino L, Stebbing J, Braga VM, et al., 2013, miR-23b regulates cytoskeletal remodeling, motility and metastasis by directly targeting multiple transcripts, Nucleic Acids Research, Vol: 41, Pages: 5400-5412, ISSN: 1362-4962
Uncontrolled cell proliferation and cytoskeletal remodeling are responsible for tumor development and ultimately metastasis. A number of studies have implicated microRNAs in the regulation of cancer cell invasion and migration. Here, we show that miR-23b regulates focal adhesion, cell spreading, cell-cell junctions and the formation of lamellipodia in breast cancer (BC), implicating a central role for it in cytoskeletal dynamics. Inhibition of miR-23b, using a specific sponge construct, leads to an increase of cell migration and metastatic spread in vivo, indicating it as a metastatic suppressor microRNA. Clinically, low miR-23b expression correlates with the development of metastases in BC patients. Mechanistically, miR-23b is able to directly inhibit a number of genes implicated in cytoskeletal remodeling in BC cells. Through intracellular signal transduction, growth factors activate the transcription factor AP-1, and we show that this in turn reduces miR-23b levels by direct binding to its promoter, releasing the pro-invasive genes from translational inhibition. In aggregate, miR-23b expression invokes a sophisticated interaction network that co-ordinates a wide range of cellular responses required to alter the cytoskeleton during cancer cell motility.
Gall TMH, Frampton AE, Krell J, et al., 2013, Blood-based miRNAs as noninvasive diagnostic and surrogative biomarkers in colorectal cancer, EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, Vol: 13, Pages: 141-145, ISSN: 1473-7159
- Author Web Link
- Cite
- Citations: 12
Lee B, Lim AK, Krell J, et al., 2013, The Efficacy of Axillary Ultrasound in the Detection of Nodal Metastasis in Breast Cancer, AMERICAN JOURNAL OF ROENTGENOLOGY, Vol: 200, Pages: W314-W320, ISSN: 0361-803X
- Author Web Link
- Cite
- Citations: 55
Gall TMH, Frampton AE, Krell J, et al., 2013, Circulating molecular markers in pancreatic cancer: ready for clinical use?, FUTURE ONCOLOGY, Vol: 9, Pages: 141-144, ISSN: 1479-6694
- Author Web Link
- Cite
- Citations: 3
Krell J, Frampton AE, Stebbing J, 2013, MicroRNAs in the cancer clinic., Front Biosci (Elite Ed), Vol: 5, Pages: 204-213
Over recent years there have been major advances in our understanding of tumour biology which have led to improved diagnostic and prognostic techniques and the development of novel targeted therapies. However the reliability of such biomarkers is questionable and the efficacy of new treatments remains predominantly limited by a combination of drug resistance, toxicity and persisting insufficiencies in our comprehension of tumour-signalling pathways. Following their recent discovery, microRNAs (miRNAs) have been established as key regulators of gene-expression, and their putative roles as oncogenes and tumour suppressor genes has provided a potentially new dimension to our clinical approach to cancer diagnosis and treatment. Their role as biomarkers and therapeutic targets is appealing but several obstacles have as yet limited our ability to translate this potential into a clinical reality. This review focuses on currently accepted roles of miRNAs in cancer pathogenesis, and highlights the challenges and breakthroughs in this field to date with relevance to the cancer clinic.
Frampton AE, Gall TMH, Krell J, et al., 2013, Is there a 'margin' for error in pancreatic cancer surgery?, FUTURE ONCOLOGY, Vol: 9, Pages: 31-34, ISSN: 1479-6694
- Author Web Link
- Cite
- Citations: 7
Frampton AE, Gall TMH, Castellano L, et al., 2013, Towards a clinical use of miRNAs in pancreatic cancer biopsies, EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, Vol: 13, Pages: 31-34, ISSN: 1473-7159
- Author Web Link
- Cite
- Citations: 16
Pellegrino L, Jacob J, Roca-Alonso L, et al., 2013, Altered expression of the miRNA processing endoribonuclease Dicer has prognostic significance in human cancers, EXPERT REVIEW OF ANTICANCER THERAPY, Vol: 13, Pages: 21-27, ISSN: 1473-7140
- Author Web Link
- Cite
- Citations: 13
Pellegrino L, Krell J, Roca-Alonso L, et al., 2013, MicroRNA-23b regulates cellular architecture and impairs motogenic and invasive phenotypes during cancer progression., Bioarchitecture, Vol: 3, Pages: 119-124
The cytoskeleton is a dynamic three dimensional structure contained within the cytoplasm of a cell, and is important in cell shape and movement, and in metastatic progression during carcinogenesis. Members of the Rho family of small GTPases, RHO, RAC and cell cycle division 42 (Cdc42) proteins regulate cytoskeletal dynamics, through the control of a panel of genes. We have recently shown that the microRNA (miRNA) miR-23b represents a central effector of cytoskeletal remodelling. It increases cell-cell interactions, modulates focal adhesion and reduces cell motility and invasion by directly regulating several genes involved in these processes.
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.